Cargando…

Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection

Background Clostridium difficile infection (CDI) is a leading cause of hospital-acquired diarrhea. Rifaximin is an antibiotic that offers marginal resistance to C. difficile bacteria. This study was conducted to evaluate the efficacy of rifaximin in metronidazole non-responsive CDI patients. Methods...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waqas, Muhammad, Mohib, Khadija, Saleem, Aniqa, LNU, Mahak, Arjumand, Sabeen, Khalil, Hafiz Habib Ur Rehman, Nosheen, Rukhshanda, Abbas, Sharmeen, Maqsood, Kanza M, Abbas, Kiran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107305/ https://www.ncbi.nlm.nih.gov/pubmed/35582554 http://dx.doi.org/10.7759/cureus.24140

Ejemplares similares

Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin
por: Tannous, George, et al.
Publicado: (2010)

Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile
por: Huhulescu, Steliana, et al.
Publicado: (2011)

Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin
por: Lao, Dominador, et al.
Publicado: (2012)

Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial
por: Menozzi, Alessandro, et al.
Publicado: (2016)

Efficacy of Oral Vancomycin, Oral Metronidazole, or IV Metronidazole Prophylaxis at Reducing the Risk of Clostridium difficile Recurrence
por: O’Connell, Matthew, et al.
Publicado: (2017)

Metronidazole-triazole conjugates: Activity against Clostridium difficile and parasites
por: Jarrad, Angie M., et al.
Publicado: (2015)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Treatment of Refractory Crohn's Disease and Pyoderma Gangrenosum with a Combination Regimen of Rifaximin, Gentamicin and Metronidazole
por: Goldberg, Neil D., et al.
Publicado: (2015)

Rifaximin Is Effective for the Treatment of Clostridium difficile—Associated Diarrhea: Results of an Open-Label Pilot Study
por: Rubin, David T., et al.
Publicado: (2011)

Characterization of a Stable, Metronidazole-Resistant Clostridium difficile Clinical Isolate
por: Lynch, Tarah, et al.
Publicado: (2013)

Plasmid-mediated metronidazole resistance in Clostridioides difficile
por: Boekhoud, Ilse M., et al.
Publicado: (2020)

Effect of sub-MIC values of metronidazole, ciprofloxacin, and imipenem on the growth and toxin production in Clostridioides difficile
por: Shayegan Mehr, Farahnaz Sadat, et al.
Publicado: (2019)

Effect of Metronidazole in Infants with Bowel Habit Change: Irrelative to the Clostridium difficile Colonization
por: Kim, Eun Jin, et al.
Publicado: (2017)

Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
por: Chong, Patrick M., et al.
Publicado: (2014)

Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole
por: Abujamel, Turki, et al.
Publicado: (2013)

Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination
por: Erikstrup, Lise Tornvig, et al.
Publicado: (2015)

Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
por: Shah, Sunish, et al.
Publicado: (2017)

Metronidazole therapy as initial treatment of Clostridium difficile infection in patients with chronic kidney disease in Korea
por: Shin, Jaeuk, et al.
Publicado: (2019)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity
por: Di, Xiuzhen, et al.
Publicado: (2015)

Sequence-Based Identification of Metronidazole-Resistant Clostridioides difficile Isolates
por: Smits, Wiep Klaas, et al.
Publicado: (2022)

488. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridium difficile Infection in Critically Ill Patients
por: Vega, Ana, et al.
Publicado: (2018)

Recurrence and mortality following treatment for Clostridum difficile infection with metronidazole or vancomycin
por: Stevens, V, et al.
Publicado: (2015)

Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial
por: Major, Giles, et al.
Publicado: (2019)

Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile
por: Boekhoud, Ilse M, et al.
Publicado: (2021)

Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection
por: Gonzales-Luna, Anne J, et al.
Publicado: (2021)

Detection of Plasmid-Mediated Resistance to Metronidazole in Clostridioides difficile from River Water
por: Cizek, Alois, et al.
Publicado: (2022)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

The Use of Rifaximin in Patients With Cirrhosis
por: Caraceni, Paolo, et al.
Publicado: (2021)

710. Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in Clostridioides difficile
por: Gonzales-Luna, Anne, et al.
Publicado: (2018)

Impact of subinhibitory concentrations of metronidazole on proteome of Clostridioides difficile strains with different levels of susceptibility
por: Doan, Tri-Hanh-Dung, et al.
Publicado: (2020)

840. Clinical Failure Rates Associated with Hemin-induced Metronidazole Resistance in Clostridioides difficile
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

Impact of Subinhibitory Concentrations of Metronidazole on Morphology, Motility, Biofilm Formation and Colonization of Clostridioides difficile
por: Doan, Tri-Hanh-Dung, et al.
Publicado: (2022)

Which is the Preferred Regimen for Non-Severe Clostridioides difficile Infection in Korea, Vancomycin or Metronidazole?
por: Kim, Jieun, et al.
Publicado: (2022)

Association of tcdA+/tcdB+ Clostridium difficile Genotype with Emergence of Multidrug-Resistant Strains Conferring Metronidazole Resistant Phenotype
por: Shayganmehr, Farahnaz-Sadat, et al.
Publicado: (2015)

1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis
por: Moran, Gisele, et al.
Publicado: (2018)

Eplerenone Treatment in Chronic Central Serous Chorioretinopathy
por: Iqbal, Faisal, et al.
Publicado: (2021)

798. Metronidazole Exposure Prior to Clostridiodes difficile Infection (CDI) is a Risk Factor for Severe C. difficile Disease in Cancer Patients
por: Francisco, Denise Marie A, et al.
Publicado: (2020)

Initial vancomycin versus metronidazole for the treatment of first-episode non-severe Clostridioides difficile infection
por: Zhang, Kevin, et al.
Publicado: (2021)

Rifaximin Therapy of Irritable Bowel Syndrome
por: Koo, Hoonmo L., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_02cffma1mk1d8hk6p07ecreobp